LABELS · 267dd735-f800-4735-ba1c-d39d00f0cee5

Depo-Medrol

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-01-21
Captured: 2026-09-09T23:37:42.544548+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

INDICATIONS AND USAGE A. FOR INTRAMUSCULAR ADMINISTRATION When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of leukemias and lymphomas. Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. FOR INTRA-ARTICULAR OR SOFT TISSUE ADMINISTRATION (see WARNINGS ) DEPO-MEDROL is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. FOR INTRALESIONAL ADMINISTRATION DEPO-MEDROL is indicated for intralesional use in alopecia areata, discoid lupus erythematosus, keloids, localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques, necrobiosis lipoidica diabeticorum. DEPO-MEDROL also may be useful in cystic tumors of an aponeurosis or tendon (ganglia).

Full extracted label fields

application numbers

NDA011757

boxed warning exact

brand names

Depo-Medrol

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=823b0010-2b57-4e76-b5ac-4a8c2963438f

generic names

METHYLPREDNISOLONE ACETATE

267dd735-f800-4735-ba1c-d39d00f0cee5

indications and usage exact

INDICATIONS AND USAGE A. FOR INTRAMUSCULAR ADMINISTRATION When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of leukemias and lymphomas. Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. FOR INTRA-ARTICULAR OR SOFT TISSUE ADMINISTRATION (see WARNINGS ) DEPO-MEDROL is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. FOR INTRALESIONAL ADMINISTRATION DEPO-MEDROL is indicated for intralesional use in alopecia areata, discoid lupus erythematosus, keloids, localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques, necrobiosis lipoidica diabeticorum. DEPO-MEDROL also may be useful in cystic tumors of an aponeurosis or tendon (ganglia).

indications and usage tables exact

is original packager

true

manufacturer names

Pharmacia & Upjohn Company LLC

matched search terms

cancer
lymphomas
tumor
tumors

package ndcs

0009-0274-01
0009-0280-02
0009-0280-51
0009-0280-03
0009-0280-52
0009-0306-02
0009-0306-12

product ndcs

0009-0274
0009-0280
0009-0306

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRALESIONAL
INTRAMUSCULAR
INTRASYNOVIAL
SOFT TISSUE

rxcuis

1358510
1358512
1358610
1358612
1358617
1358619

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00100.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 224
end exclusive: true
exact text: INDICATIONS AND USAGE A. FOR INTRAMUSCULAR ADMINISTRATION When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condi
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 0

current approval status

not_reconciled

duplicate text group

dup-0937f2a029cc7cf34ec7

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-e6e65a4038f9e9ac9d33

label id

267dd735-f800-4735-ba1c-d39d00f0cee5

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 24
end exclusive: true
exact text: INDICATIONS AND USAGE A.
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22267dd735-f800-4735-ba1c-d39d00f0cee5%22

spl effective date

2026-01-21

spl set id

823b0010-2b57-4e76-b5ac-4a8c2963438f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 2 · positive indication candidate

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 771
end exclusive: true
exact text: INDICATIONS AND USAGE A. FOR INTRAMUSCULAR ADMINISTRATION When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 0

current approval status

not_reconciled

duplicate text group

dup-4fbe17870aa77d3f5e83

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-b025499cc125bda87391

label id

267dd735-f800-4735-ba1c-d39d00f0cee5

positive predicate support span

end: 306
end exclusive: true
exact text: is indicated
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 294

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 571
end exclusive: true
exact text: FOR INTRAMUSCULAR ADMINISTRATION When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions.
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 25

source url

https://api.fda.gov/drug/label.json?search=id%3A%22267dd735-f800-4735-ba1c-d39d00f0cee5%22

spl effective date

2026-01-21

spl set id

823b0010-2b57-4e76-b5ac-4a8c2963438f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 3 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 940
end exclusive: true
exact text: allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 372

current approval status

not_reconciled

duplicate text group

dup-b9f4dd17f0b1e957bea2

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-9ddda670a238cfc9a683

label id

267dd735-f800-4735-ba1c-d39d00f0cee5

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 740
end exclusive: true
exact text: Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 572

source url

https://api.fda.gov/drug/label.json?search=id%3A%22267dd735-f800-4735-ba1c-d39d00f0cee5%22

spl effective date

2026-01-21

spl set id

823b0010-2b57-4e76-b5ac-4a8c2963438f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1325
end exclusive: true
exact text: ckness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) he
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 541

current approval status

not_reconciled

duplicate text group

dup-74e50253ff66a1385818

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-e60c96ff289be686f0da

label id

267dd735-f800-4735-ba1c-d39d00f0cee5

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1125
end exclusive: true
exact text: Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 741

source url

https://api.fda.gov/drug/label.json?search=id%3A%22267dd735-f800-4735-ba1c-d39d00f0cee5%22

spl effective date

2026-01-21

spl set id

823b0010-2b57-4e76-b5ac-4a8c2963438f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1476
end exclusive: true
exact text: ticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia.
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 926

current approval status

not_reconciled

duplicate text group

dup-32c025fefe7551d6002e

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-14f82a2e7cc66734a266

label id

267dd735-f800-4735-ba1c-d39d00f0cee5

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1276
end exclusive: true
exact text: Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis.
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 1126

source url

https://api.fda.gov/drug/label.json?search=id%3A%22267dd735-f800-4735-ba1c-d39d00f0cee5%22

spl effective date

2026-01-21

spl set id

823b0010-2b57-4e76-b5ac-4a8c2963438f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1676
end exclusive: true
exact text: ociated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemot
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 1077

current approval status

not_reconciled

duplicate text group

dup-3a89a03fb929943e3ab3

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-23a7ed5c18bb0f1af70d

label id

267dd735-f800-4735-ba1c-d39d00f0cee5

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1476
end exclusive: true
exact text: Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia.
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 1277

source url

https://api.fda.gov/drug/label.json?search=id%3A%22267dd735-f800-4735-ba1c-d39d00f0cee5%22

spl effective date

2026-01-21

spl set id

823b0010-2b57-4e76-b5ac-4a8c2963438f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1883
end exclusive: true
exact text: Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of leukemias and lymphomas. Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Symp
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 1277

current approval status

not_reconciled

duplicate text group

dup-d4783cbafc27192e1a89

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-76c56ac62938aa58f834

label id

267dd735-f800-4735-ba1c-d39d00f0cee5

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1683
end exclusive: true
exact text: Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 1477

source url

https://api.fda.gov/drug/label.json?search=id%3A%22267dd735-f800-4735-ba1c-d39d00f0cee5%22

spl effective date

2026-01-21

spl set id

823b0010-2b57-4e76-b5ac-4a8c2963438f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1959
end exclusive: true
exact text: aneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of leukemias and lymphomas. Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory cond
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 1484

current approval status

not_reconciled

duplicate text group

dup-b3ff21b8dbe78a727d52

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-5fa8bc4737966813e5e7

label id

267dd735-f800-4735-ba1c-d39d00f0cee5

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1759
end exclusive: true
exact text: Neoplastic Diseases : For palliative management of leukemias and lymphomas.
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 1684

source url

https://api.fda.gov/drug/label.json?search=id%3A%22267dd735-f800-4735-ba1c-d39d00f0cee5%22

spl effective date

2026-01-21

spl set id

823b0010-2b57-4e76-b5ac-4a8c2963438f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2056
end exclusive: true
exact text: meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of leukemias and lymphomas. Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 1560

current approval status

not_reconciled

duplicate text group

dup-4fd41b689e0be64fdf7e

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-6622741e08f59cb2fd81

label id

267dd735-f800-4735-ba1c-d39d00f0cee5

positive predicate support span

Source null

qualifier mentions

context exact
Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy.
kind
biomarker
polarity
not_inferred
span
end
1855
end exclusive
true
exact text
metastatic brain tumor or craniotomy
label id
267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start
1819
context exact
Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy.
kind
stage_or_setting
polarity
not_inferred
span
end
1855
end exclusive
true
exact text
metastatic brain tumor or craniotomy
label id
267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start
1819

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1856
end exclusive: true
exact text: Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy.
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 1760

source url

https://api.fda.gov/drug/label.json?search=id%3A%22267dd735-f800-4735-ba1c-d39d00f0cee5%22

spl effective date

2026-01-21

spl set id

823b0010-2b57-4e76-b5ac-4a8c2963438f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2206
end exclusive: true
exact text: ituberculous chemotherapy. Neoplastic Diseases : For palliative management of leukemias and lymphomas. Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated p
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 1657

current approval status

not_reconciled

duplicate text group

dup-bec185e685dda6c8627f

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-0e5ad9c8b67ffc8d2d74

label id

267dd735-f800-4735-ba1c-d39d00f0cee5

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 2006
end exclusive: true
exact text: Ophthalmic Diseases : Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 1857

source url

https://api.fda.gov/drug/label.json?search=id%3A%22267dd735-f800-4735-ba1c-d39d00f0cee5%22

spl effective date

2026-01-21

spl set id

823b0010-2b57-4e76-b5ac-4a8c2963438f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2340
end exclusive: true
exact text: primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, sympto
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 1807

current approval status

not_reconciled

duplicate text group

dup-569e7b97668b4d849aff

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-10d85b5e307502b699a3

label id

267dd735-f800-4735-ba1c-d39d00f0cee5

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 2140
end exclusive: true
exact text: Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus.
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 2007

source url

https://api.fda.gov/drug/label.json?search=id%3A%22267dd735-f800-4735-ba1c-d39d00f0cee5%22

spl effective date

2026-01-21

spl set id

823b0010-2b57-4e76-b5ac-4a8c2963438f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2558
end exclusive: true
exact text: inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing sp
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 1941

current approval status

not_reconciled

duplicate text group

dup-c139b7eb2205be4e791b

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-a5de8a7682db875d0391

label id

267dd735-f800-4735-ba1c-d39d00f0cee5

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 2358
end exclusive: true
exact text: Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 2141

source url

https://api.fda.gov/drug/label.json?search=id%3A%22267dd735-f800-4735-ba1c-d39d00f0cee5%22

spl effective date

2026-01-21

spl set id

823b0010-2b57-4e76-b5ac-4a8c2963438f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2910
end exclusive: true
exact text: es : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. FOR INTRA-ARTICULAR OR SOFT TISSUE ADMINISTRATION (see WARNINGS ) DEPO-MEDROL is indicated as adjunctive thera
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 2159

current approval status

not_reconciled

duplicate text group

dup-3d32af4f68752366028c

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-4070b5ec6ba4702151e9

label id

267dd735-f800-4735-ba1c-d39d00f0cee5

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 2710
end exclusive: true
exact text: Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 2359

source url

https://api.fda.gov/drug/label.json?search=id%3A%22267dd735-f800-4735-ba1c-d39d00f0cee5%22

spl effective date

2026-01-21

spl set id

823b0010-2b57-4e76-b5ac-4a8c2963438f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 14 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2996
end exclusive: true
exact text: hritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. FOR INTRA-ARTICULAR OR SOFT TISSUE ADMINISTRATION (see WARNINGS ) DEPO-MEDROL is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerb
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 2511

current approval status

not_reconciled

duplicate text group

dup-81aa6ee5f11dc121c9b7

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-5bd6947b0b48031cff77

label id

267dd735-f800-4735-ba1c-d39d00f0cee5

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 2796
end exclusive: true
exact text: For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 2711

source url

https://api.fda.gov/drug/label.json?search=id%3A%22267dd735-f800-4735-ba1c-d39d00f0cee5%22

spl effective date

2026-01-21

spl set id

823b0010-2b57-4e76-b5ac-4a8c2963438f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 15 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2999
end exclusive: true
exact text: oid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. FOR INTRA-ARTICULAR OR SOFT TISSUE ADMINISTRATION (see WARNINGS ) DEPO-MEDROL is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbati
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 2597

current approval status

not_reconciled

duplicate text group

dup-73af3fd15cf9e69b042a

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-7afa19334174e68d4fff

label id

267dd735-f800-4735-ba1c-d39d00f0cee5

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 2799
end exclusive: true
exact text: B.
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 2797

source url

https://api.fda.gov/drug/label.json?search=id%3A%22267dd735-f800-4735-ba1c-d39d00f0cee5%22

spl effective date

2026-01-21

spl set id

823b0010-2b57-4e76-b5ac-4a8c2963438f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 16 · positive indication candidate

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
positive_statement_also_contains_qualification_review_required

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3356
end exclusive: true
exact text: arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. FOR INTRA-ARTICULAR OR SOFT TISSUE ADMINISTRATION (see WARNINGS ) DEPO-MEDROL is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. FOR INTRALESIONAL ADMINISTRATION DEPO-MEDROL is indicated for intralesional use in alopecia areata, discoid lupus erythematosus, keloids, localized hypertrophic, infiltrated, inflammatory lesions
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 2600

current approval status

not_reconciled

duplicate text group

dup-8f35afd132fa704ae129

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-98e7f17967acc0e92533

label id

267dd735-f800-4735-ba1c-d39d00f0cee5

positive predicate support span

end: 2890
end exclusive: true
exact text: is indicated
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 2878

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 3156
end exclusive: true
exact text: FOR INTRA-ARTICULAR OR SOFT TISSUE ADMINISTRATION (see WARNINGS ) DEPO-MEDROL is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 2800

source url

https://api.fda.gov/drug/label.json?search=id%3A%22267dd735-f800-4735-ba1c-d39d00f0cee5%22

spl effective date

2026-01-21

spl set id

823b0010-2b57-4e76-b5ac-4a8c2963438f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 17 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3359
end exclusive: true
exact text: atient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. FOR INTRALESIONAL ADMINISTRATION DEPO-MEDROL is indicated for intralesional use in alopecia areata, discoid lupus erythematosus, keloids, localized hypertrophic, infiltrated, inflammatory lesions of
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 2957

current approval status

not_reconciled

duplicate text group

dup-6562635dad0834972017

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-e82744455fb481af79a3

label id

267dd735-f800-4735-ba1c-d39d00f0cee5

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 3159
end exclusive: true
exact text: C.
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 3157

source url

https://api.fda.gov/drug/label.json?search=id%3A%22267dd735-f800-4735-ba1c-d39d00f0cee5%22

spl effective date

2026-01-21

spl set id

823b0010-2b57-4e76-b5ac-4a8c2963438f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 18 · positive indication candidate

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 3583
end exclusive: true
exact text: ent over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. FOR INTRALESIONAL ADMINISTRATION DEPO-MEDROL is indicated for intralesional use in alopecia areata, discoid lupus erythematosus, keloids, localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques, necrobiosis lipoidica diabeticorum. DEPO-MEDROL also may be useful in cystic tumors of an aponeurosis or tendon (ganglia).
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 2960

current approval status

not_reconciled

duplicate text group

dup-7382127a3d4daa1d83ea

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-53e9b14906694d0748a4

label id

267dd735-f800-4735-ba1c-d39d00f0cee5

positive predicate support span

end: 3217
end exclusive: true
exact text: is indicated
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 3205

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 3496
end exclusive: true
exact text: FOR INTRALESIONAL ADMINISTRATION DEPO-MEDROL is indicated for intralesional use in alopecia areata, discoid lupus erythematosus, keloids, localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques, necrobiosis lipoidica diabeticorum.
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 3160

source url

https://api.fda.gov/drug/label.json?search=id%3A%22267dd735-f800-4735-ba1c-d39d00f0cee5%22

spl effective date

2026-01-21

spl set id

823b0010-2b57-4e76-b5ac-4a8c2963438f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 19 · unclassified context

application numbers

NDA011757

brand names

Depo-Medrol

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3583
end exclusive: true
exact text: localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques, necrobiosis lipoidica diabeticorum. DEPO-MEDROL also may be useful in cystic tumors of an aponeurosis or tendon (ganglia).
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 3297

current approval status

not_reconciled

duplicate text group

dup-64f3c77d92e9ab747392

extraction review status

automated_candidate_pending_source_review

generic names

METHYLPREDNISOLONE ACETATE

ind-span-9fd28f199dde6311a174

label id

267dd735-f800-4735-ba1c-d39d00f0cee5

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 3583
end exclusive: true
exact text: DEPO-MEDROL also may be useful in cystic tumors of an aponeurosis or tendon (ganglia).
label id: 267dd735-f800-4735-ba1c-d39d00f0cee5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: f362048a9e628765a78f440a89afe5157b153948a053e7c53354da25c16830d1
start: 3497

source url

https://api.fda.gov/drug/label.json?search=id%3A%22267dd735-f800-4735-ba1c-d39d00f0cee5%22

spl effective date

2026-01-21

spl set id

823b0010-2b57-4e76-b5ac-4a8c2963438f

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice